



New Hampshire AIDS Drug Assistance Program

Prior Authorization

Adenosine triphosphate-citrate lyase inhibitor Medication

DATE OF MEDICATION REQUEST: / /

SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED

LAST NAME:

FIRST NAME:

MEDICAID ID NUMBER:

DATE OF BIRTH:

GENDER: Male Female

Drug Name:

Strength:

Dosing Directions:

Length of Therapy:

SECTION II: PRESCRIBER INFORMATION

LAST NAME:

FIRST NAME:

SPECIALTY:

NPI NUMBER:

PHONE NUMBER:

FAX NUMBER:

SECTION III: CLINICAL HISTORY

1. Does the patient have heterozygous familial hypercholesterolemia (HeFH)? Yes No
2. Does the patient have established atherosclerotic cardiovascular disease (ASCVD)? Yes No
3. Is the patient receiving maximally-tolerated statin? Yes No
If yes, list medication: _____
4. Will the patient continue to receive the statin? Yes No
5. Has the patient achieved the target LDL-C with the current regimen? Yes No

(Form continued on the next page.)



New Hampshire AIDS Drug Assistance Program

Prior Authorization

Adenosine triphosphate-citrate lyase inhibitor Medication

DATE OF MEDICATION REQUEST: / /

PATIENT LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PATIENT FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SECTION III: CLINICAL HISTORY (Continued)

6. In which high-risk group would the patient be considered?:

- Extremely high risk with an LDL-C \geq 70 mg/dL
- Very high risk with an LDL-C \geq 100 mg/dL
- High risk with an LDL-C \geq 130 mg/dL

7. Please list lipid panel results: _____

8. *Nexlizet™ only*: Is the patient currently receiving gemfibrozil? Yes No

I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

PRESCRIBER'S SIGNATURE: _____ DATE: _____